SVRA

Savara Inc

4.82

Oct 30 • 3:59 PM ET -0.13 (-2.63%)

4.87

Aftermarket • 7:52 PM ET +0.05 (1.04%)

Healthcare Biotechnology USA Small NASD

Peers: AVLN INSM MNKD RARE PLRX ZVRA VCRE PHAR ARMP PULM

| Held by: VTI IWM XBI VXF IWO VTWO SCHA IBB LFSC IWC

Scroll to Statements

Index	RUT
Market Cap	990.32M
Enterprise Value	847.70M
Income	-139.31M
Sales	0.00M
Book/sh	0.70
Cash/sh	0.84
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	70
IPO	Oct 16, 2000

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	6.89
P/C	5.72
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	10.13
Current Ratio	10.13
Debt/Eq	0.21
LT Debt/Eq	0.21
Option/Short	Yes / Yes

EPS (ttm)	-0.58
EPS next Y	-0.39
EPS next Q	-0.16
EPS this Y	-19.81%
EPS next Y	38.58%
EPS next 5Y	-
EPS past 3/5Y	-28.87% 8.57%
Sales past 3/5Y	- -
EPS Y/Y TTM	-12.40%
Sales Y/Y TTM	-
EPS Q/Q	-12.95%
Sales Q/Q	-
Earnings	Aug 11 AMC
EPS/Sales Surpr.	-12.28% -

Insider Own	49.88%
Insider Trans	-0.38%
Inst Own	67.22%
Inst Trans	1.64%
ROA	-78.28%
ROE	-105.48%
ROIC	-80.17%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	1.88%
SMA50	-5.02%
SMA200	-10.60%
Trades

Shs Outstand	205.40M
Shs Float	102.98M
Short Float	27.91%
Short Ratio	14.56
Short Interest	28.74M
52W High	7.01 -31.19%
52W Low	3.86 24.87%
Volatility	6.56% 6.15%
ATR (14)	0.28
RSI (14)	49.32
Beta	0.30
Rel Volume	0.72
Avg Volume	1.97M
Volume	1,411,877

Perf Week	14.22%
Perf Month	-4.46%
Perf Quarter	-9.57%
Perf Half Y	-5.86%
Perf YTD	-20.07%
Perf Year	12.09%
Perf 3Y	31.34%
Perf 5Y	315.52%
Perf 10Y	-11.72%
Recom	1.00
Target Price	11.06
Prev Close	4.95
Price	4.82
Change %	-2.63%

Consensus

Strong Buy

Avg. Price Target

$11.06

Implied Upside

+129.5%

Analysts11incl. previous ratings

Rating Distribution8 Buy · 3 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 07, 2026	Initiated	JJP Morgan	Overweight	$12	+149.0%
Apr 24, 2026	Resumed	OOppenheimer	Outperform	$9 → $11	+128.2%
Oct 20, 2025	Initiated	WWells Fargo	Overweight	$7	+45.2%
Aug 15, 2025	Upgrade	HH.C. Wainwright	Neutral → Buy	$5	+3.7%
May 29, 2025	Downgrade	HH.C. Wainwright	Buy → Neutral	$2	-58.5%
Dec 20, 2024	Initiated	WWells Fargo	Overweight	$8	+66.0%
Nov 13, 2024	Downgrade	EEvercore ISI	Outperform → In-line	$7 → $5	+3.7%
Feb 15, 2024	Initiated	JJMP Securities	Mkt Outperform	$8	+66.0%
Nov 07, 2023	Initiated	GGuggenheim	Buy	$7	+45.2%
May 16, 2023	Upgrade	JJefferies	Hold → Buy	$2 → $4	-17.0%
Mar 31, 2023	Downgrade	JJefferies	Buy → Hold	$2	-58.5%
Mar 16, 2021	Initiated	PPiper Sandler	Overweight	$7	+45.2%
Mar 15, 2021	Initiated	OOppenheimer	Outperform	$4	-17.0%
Jun 13, 2019	Reiterated	HH.C. Wainwright	Buy	$22 → $6	+24.5%
Jun 13, 2019	Downgrade	LLadenburg Thalmann	Buy → Neutral	$21 → $3	-37.8%
Jun 13, 2019	Downgrade	JJMP Securities	Mkt Outperform → Mkt Perform
Aug 13, 2018	Resumed	RROTH Capital	Neutral	$12	+149.0%
Jan 03, 2018	Initiated	LLadenburg Thalmann	Buy	$35	+626.1%
Sep 27, 2017	Resumed	RROTH Capital	Buy	$40	+729.9%
Sep 22, 2017	Initiated	JJefferies	Buy	$20	+314.9%

Oct-21-26 01:10PM	Savara Presented New Data Showing Molgramostim Inhalation Solution (Molgramostim) Treatment Effects in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Patients with Mild Diffusion Impairment (Business Wire)
Oct-12-26 04:05PM	Savara to Present New Analysis from the IMPALA Clinical Trial and Deliver Encore Presentation of Long-Term Data on Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2026 (Business Wire)
Oct-11-26 12:43PM	Savara Has Lost 30% Since December: JPMorgan Sees 146% Upside (TIKR)
Aug-24-26 04:05PM	Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026 (Business Wire)
Aug-20-26 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
04:05PM	Loading…
Aug-11-26 04:05PM	Savara Reports Second Quarter 2026 Financial Results and Provides Business Update (Business Wire)
Aug-07-26 11:39AM	What Insmed Stock's Premium Is Actually Buying (Trefis)
Jul-30-26 08:05AM	Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041 (Business Wire)
Jun-12-26 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Jun-08-26 04:05PM	Savara Announces Chief Financial and Administrative Officer Transition (Business Wire)
May-27-26 04:05PM	Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference (Business Wire)
May-20-26 08:15AM	Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026 (Business Wire) +7.63%
May-19-26 02:15PM	Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
May-18-26 02:55PM	Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
May-12-26 04:05PM	Savara Reports First Quarter Financial Results and Provides Business Update (Business Wire)
04:05PM	Loading…
May-11-26 04:05PM	Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference (Business Wire)
Apr-17-26 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Apr-15-26 04:05PM	Savara Announces the U.S. Food & Drug Administration (FDA) Has Extended the Review Period for the Molgramostim Inhalation Solution (Molgramostim) Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) (Business Wire)
Apr-14-26 08:05AM	Savara To Present New Data at the American Thoracic Society (ATS) 2026 International Conference (Business Wire)
Apr-07-26 08:05AM	Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) (Business Wire)
Mar-30-26 08:05AM	Savara Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) for MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) (Business Wire)
Mar-13-26 08:05AM	Savara Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Update (Business Wire)
Mar-06-26 04:05PM	Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) (Business Wire)
Mar-04-26 04:05PM	Savara Announces Participation in 2026 Citizens Life Sciences Conference (Business Wire)
Mar-01-26 07:36PM	Savara Highlights FDA Priority Review for Molbreevi as Aug. 22 PDUFA Date Nears (MarketBeat)
Feb-20-26 04:15PM	Savara Announces the U.S. Food and Drug Administration (FDA) Filed the MOLBREEVI* Biologics License Application (BLA) in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) (Business Wire)
Feb-15-26 11:03AM	Savara Eyes August PDUFA for MOLBREEVI as FDA BLA Filing Decision Nears, Execs Say at Summit (MarketBeat)
Feb-13-26 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Feb-04-26 04:05PM	Savara Announces Participation in Upcoming Investor Healthcare Conferences (Business Wire) -5.30%
Jan-27-26 08:05AM	Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI* (Business Wire)
04:05PM	Loading…
Jan-16-26 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Jan-08-26 04:05PM	PANTHERx Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI* (Business Wire)
Dec-22-25 08:30AM	Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) (Business Wire) +6.94%
Dec-17-25 08:05AM	Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-11-25 08:05AM	Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI* (Business Wire)
Dec-02-25 08:05AM	Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow Nebulizer System (Business Wire)
Dec-01-25 01:23PM	Savara (SVRA) Climbs 27.8% Ahead of 2 Health Conferences (Insider Monkey) -7.15%
Nov-20-25 04:05PM	Savara Announces Participation in Upcoming Investor Healthcare Conferences (Business Wire) +5.35%
Nov-12-25 04:05PM	Savara Reports Third Quarter 2025 Financial Results and Provides Business Update (Business Wire)
Nov-03-25 04:05PM	Savara Announces Participation in Upcoming Investor Healthcare Conferences (Business Wire)
02:56AM	Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SVRA (PR Newswire)
Oct-31-25 04:05PM	Savara Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $149.5M (Business Wire)
Oct-30-25 11:29PM	What Does Wall Street Think About Savara Inc. (SVRA)? (Insider Monkey)
Oct-29-25 09:43PM	Savara Announces Pricing of $130.0 Million Public Offering of Common Stock and Pre-funded Warrants (Business Wire)
04:07PM	Savara Announces Proposed Public Offering (Business Wire)
04:01PM	Savara announces $75M Royalty Funding Agreement with RTW to Support the Potential Launch of MOLBREEVI* in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) (Business Wire)
11:57AM	Savara Inc. (SVRA) To Present Molgramostim Data in the Fight Against Infections (Insider Monkey)
Oct-17-25 08:05AM	Savara Announces Chief Medical Officer (CMO) Transition (Business Wire)
Oct-13-25 04:59PM	Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SVRA (PR Newswire)
Oct-10-25 09:00AM	Savara Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - SVRA (PR Newswire)
Oct-07-25 07:40AM	Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SVRA (PR Newswire)
Oct-02-25 04:05PM	Savara Announces Encore Presentations of Results From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at CHEST 2025 (Business Wire)
Sep-29-25 02:00AM	Savara Presents New Data From the Phase 3 IMPALA-2 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society (ERS) Congress 2025 (Business Wire)
Sep-25-25 04:37PM	Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SVRA (PR Newswire)
Sep-24-25 04:25PM	Did You Lose Money on Savara Inc. (SVRA)? Levi & Korsinsky Urges Investors to Act Before November 7, 2025 (Newsfile)
Sep-23-25 10:53AM	Savara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights SVRA (Business Wire)
Sep-20-25 02:43AM	Guggenheim Lifts Savara (SVRA) Price Target on Pulmonary Alveolar Proteinosis Opportunity (Insider Monkey)
Sep-11-25 04:18PM	Investors in Savara Inc. (SVRA): Protect Your Rights - Contact Levi & Korsinsky Before November 7, 2025 (Newsfile) -6.27%
Sep-02-25 09:00AM	Savara Announces New U.S. Health Claims Data Analysis Finds Over 50% Increase in the Estimated Number of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) Patients Compared to Previous Claims Analysis (Business Wire)
Aug-26-25 04:05PM	Savara Announces Participation in Upcoming Investor Healthcare Conferences (Business Wire) +5.41%
Aug-23-25 04:16AM	Savara Inc. (SVRA) Upgraded to Buy After FDA CMC Breakthrough (Insider Monkey)
Aug-20-25 05:15PM	New England Journal of Medicine (NEJM) to Publish Results From Savara's Pivotal Phase 3 IMPALA-2 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) (Business Wire)
Aug-18-25 08:05AM	Savara to Present New Data from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the European Respiratory Society Congress 2025 (Business Wire)
Aug-13-25 08:05AM	Savara Reports Second Quarter 2025 Financial Results and Provides a Business Update (Business Wire)
Jul-18-25 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
May-27-25 08:05AM	Savara Receives Refusal to File (RTF) Letter From the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for MOLBREEVI* to Treat Patients With Autoimmune Pulmonary Alveolar Proteinosis (autoimmune PAP) (Business Wire) -31.69%
07:53AM	Biogen strikes RNAi deal with City; Aurion withdraws IPO (BioPharma Dive)
May-23-25 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
May-22-25 09:05AM	Savara Announces Participation in Jefferies Global Healthcare Conference (Business Wire)
May-21-25 11:16AM	Savara Inc. (SVRA): Analysts See 212% Upside Potential (Insider Monkey) -7.18%
May-18-25 02:30PM	Savara Presented New Data From Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at American Thoracic Society Conference (ATS) 2025 (Business Wire)
May-13-25 04:05PM	Savara Reports First Quarter 2025 Financial Results and Provides a Business Update (Business Wire)
May-12-25 04:05PM	Savara Announces Participation in the H.C. Wainwright & Co. 3rd Annual BioConnect Investor Conference (Business Wire) +5.59%
May-01-25 04:05PM	Savara Announces Participation in the Upcoming Citizens Life Sciences Conference (Business Wire)
Apr-21-25 11:16AM	Savara: Make-It-Or-Break-It Molbreevi BLA Filing (Seeking Alpha)
Apr-11-25 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire) +10.61%
Apr-07-25 04:05PM	Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences (Business Wire) -5.45%
Mar-27-25 07:05AM	Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update (Business Wire)
Mar-26-25 04:45PM	Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital (Business Wire)
04:05PM	Savara Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
Mar-17-25 08:05AM	Savara to Present New Data From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society International Conference 2025 (Business Wire) +7.66%
Mar-06-25 08:05AM	Savara Announces U.S. Launch of the aPAP ClearPath Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)
Mar-03-25 04:15PM	Savara Announces Participation in the Leerink Global Healthcare Conference (Business Wire) -6.83%
Feb-14-25 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Jan-30-25 08:39AM	Savara Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Published in ERJ Open Research (Business Wire)
Jan-29-25 04:05PM	Savara Announces Participation in Upcoming Healthcare Investor Conferences (Business Wire)
Dec-23-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
Dec-18-24 04:05PM	Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire) -6.21% +6.95%
Dec-17-24 04:05PM	Savara Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Nov-22-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
08:05AM	Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024 (Business Wire)
Nov-13-24 01:21PM	Evercore Downgrades Savara on Manufacturing Concerns for Lung Disease Drug Candidate (GuruFocus.com) -15.14%
08:05AM	Savara Announces Participation in Upcoming Healthcare Conferences (Business Wire)
Nov-12-24 08:05AM	Savara Reports Third Quarter 2024 Financial Results and Provides Business Update (Business Wire) -5.90%
Nov-04-24 04:05PM	Savara to Present at the Guggenheim Inaugural Healthcare Innovation Conference (Business Wire)
Oct-22-24 08:05AM	Savara Announces the Rare Lung Disease, Autoimmune Pulmonary Alveolar Proteinosis (aPAP), is Highlighted on a New Episode of The Balancing Act Airing on Lifetime TV (Business Wire)
Oct-18-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire) -5.05%
Oct-01-24 08:05AM	Savara Announces Patient Journey Map for People Living with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Accepted for Poster Presentation at the CHEST 2024 Annual Meeting (Business Wire) -5.90%
Sep-27-24 04:05PM	Savara Announces New Employment Inducement Grant (Business Wire)
08:05AM	Savara Announces Expanded Access Program (EAP) for Molgramostim Inhalation Solution (Molgramostim) for Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Business Wire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lowrance David L	Chief Financial Officer	Jun 22 '26	Option Exercise	1.76	580,187	1,021,116	983,947	Jun 22 08:18 PM
Lowrance David L	Chief Financial Officer	Jun 22 '26	Sale	5.68	394,528	2,241,432	536,032	Jun 22 08:18 PM
Lowrance David L	Officer	Jun 22 '26	Proposed Sale	5.65	394,528	2,229,000		Jun 22 03:09 PM
Lowrance David L	Chief Financial Officer	Mar 18 '26	Option Exercise	1.60	366,747	588,455	552,550	Mar 20 04:16 PM
McCracken Joseph S	Director	Feb 16 '26	Option Exercise	1.76	1,807	3,180	302,644	Feb 17 05:30 PM
RAMSAY DAVID A	Director	Dec 19 '25	Sale	6.06	20,000	121,220	2,533,642	Dec 19 05:00 PM
RAMSAY DAVID A	Director	Dec 18 '25	Proposed Sale	6.11	20,000	122,200		Dec 18 11:17 AM
Elam Nevan C	Director	Dec 02 '25	Option Exercise	1.46	5,860	8,556	68,360	Dec 04 06:55 PM
Hawkins Richard J	Director	Nov 14 '25	Option Exercise	1.46	5,860	8,556	121,326	Nov 17 04:38 PM

Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its program includes molgramostim, which is an inhaled formulation of recombinant human GM-CSF and being developed for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in December 1995 and is headquartered in Langhorne, PA.

M.B.A.Mr. Matthew Pauls J.D.

COO & CFOMr. Robert Matthew Lutz M.B.A.

Ph.D.Dr. Yasmine Wasfi M.D.

Chief Legal OfficerMs. Kate McCabe J.D.

Chief People OfficerMs. Megan Carpenter

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SVRA

Savara Inc

Upgrade your Finviz experience